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For every patient and doctor, and for
every scientist peering at a flask of
deranged cells, this book connects the
moment to the multiple voices that have
played off each other since the first person
squeezed a painful lump and wondered
what to do.
Reading Siddhartha Mukherjee’s The
Emperor of all Maladies: The Biography of
Cancer, the full accomplishment of this
book slowly dawned on me. The story
begins with a real patient with fulminant
leukemia and inevitable terror, and a
young doctor not sure of the course. The
protocols of recent times are applied. But
where did those treatments come from?
The author, working in the Dana-Farber
Cancer Institute and tracing back the
history, comes to a hero of the past,
Sidney Farber.
In the 1940s, what did leukemia seem
like to Farber and to his patients? In fact,
Farber, originally a pathologist, did not see
patients. For the childhood leukemias that
fascinated Farber, the children came to the
hospital, were diagnosed, and over months
died horrible deaths that devastated their
families. There was no treatment. But
Farber thought the right chemical combi-
nations could be found to control and
ultimately beat the disease. It was a heroic
goal, but heroes often start as pariahs. And
perhaps, in this case, the oncologists who
shunned Farber had a point.
The theory of chemotherapy was sim-
ple. Poison the patient with chemicals that
kill cells, and hope that cancer cells die
faster than other cells. Hope was indeed a
big part of the early studies. The chemical
agents were potent poisons that worked
very well, but their specificity for cancer
cells as opposed to normal cells was not
always so great. To knock the cancer back
took a lot of poison, which was awful for
the patient. Often, the only chance of
knocking out the cancer required poison-
ing the patient right to, and too often past,
the threshold of death. If the cancer was
knocked out, the child had a brief reprieve.
Soon enough the disease came roaring
back, more aggressive and untreatable
than before.
Oncologists wanted nothing to do with
Farber, and did not want him ‘‘experi-
menting’’ on children in their hospital.
The treatments were horrible, often more
horrible than the disease itself. The
supposed miracle cures created false hope,
and then failed terribly. Farber was
determined. He was more than deter-
mined. He had to find a way to treat and
cure cancer. As with so many of the great
characters in cancer’s story, no was not an
answer. It was an obstacle to be overcome,
just like the disease itself.
Farber developed the chemicals, getting
others to help. He came out of the lab, got
some beds in the deepest, coldest, most
isolated part of the hospital. At least,
thought the other oncologists, don’t let
anyone see what he is doing. Farber
recruited nurses and doctors, found pa-
tients whose families realized there was no
other hope, guessed at some dosages,
started injecting, and ran the ward. It
was far from a clinical trial in the modern
sense, but it was a real trial. Suffering and
death were the norm, but that was already
the baseline from which they started.
The author evokes the people, the
failure, the eventual halting progress.
Once Farber’s voice has been introduced,
the story moves off to develop other voices.
But Farber continues to echo in the
background. We may find ourselves in
the modern Dana-Farber hospital walking
by his old office, or hear Farber’s spirit
resonate with the personalities and the
approaches of the great cancer surgeons
who also tried to cure by first trying to
destroy. How far toward death should the
treatment go? How much horror in the
often temporary cure justifies the journey
through hell to get there? If it takes a great
personal ego to smash through the obsta-
cles of professional resistance to develop
radical chemotherapy or radical surgery,
can those giant egos learn and change as
they are inevitably found to be partly right
and partly wrong?
Patients, doctors, treatments. Heroes,
dubious behavior, sometimes by the same
people. This is already a rich story,
beautifully told. The author has that very
rare master’s touch, evoking fully yet with
the fewest of strokes. As readers, the
experienced doctor, the bench scientist,
and the patient will all move from sketch
to realized story in different ways. There is
detail and depth, but little to hinder.
With the patient-doctor-treatment
counterpoint well established, the author
adds new voices. Treatments through the
1960s progressed, clinical trial procedures
were established, broad cooperative re-
search programs emerged. But the success
of treatments was confined to a few types
of rare cancers. Overall, the total cancer
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was being learned about where the cancer
burden came from. A lot came from
cigarettes. We get the story of the
epidemiological research, with new heroes.
Resistance always comes from some-
where. This time, it’s the tobacco industry.
You know the story in broad outline. The
details resonate with what was being
learned about the causes of cancer, with
early detection through mammograms
and the Pap smear, and with the com-
plexities and controversies over the effica-
cy of screening. Competing interests arise
and economics plays a role. There is
increasing activism of the public in
shaping research and health-related poli-
cies.
Until the 1970s, so little was understood
about cancer and about how treatments
worked, that it was all a black box.
Presented with a disease, one poisoned or
cut deeply and hoped the patient survived
and the cancer died. By the 1970s, we
learned to measure better and run proper
trials, to cut a bit more or a bit less, to use
different combinations of poisons. It was
all empirical, in that little was really known
about how different cancers differ and why
individuals respond differently to the same
treatments. And why, for many cancers,
did death soon occur at nearly the same
rate as before treatments existed?
Then we found some of the genes that
mutated in cancers. We learned the
biochemical actions of different potential
treatments. Could we learn to match the
specific changes in certain tumors to
particular drugs designed to treat the
specific malfunctions? Briefly, the answer
is that we did in a few cases, we are still
learning, and many people think great
progress is ahead.
By this point in the story, you are well
versed in the pace of history. At any time,
always slow progress up to that point, new
promise imagined ahead. But, as the
author develops the story of recent re-
search, you also feel the accelerating pace
of change on top of that slow march
through time. It was only 15 years ago that
we first began to get any real genetic
understanding, and those first clues were
scattered and unclear. It was only a couple
of years ago that we began to measure the
actual genetic changes in tumors. And we
know that genetic changes are only a part
of the story. We have hints about the other
factors, and just now can start to measure
those factors such as epigenetic changes in
DNA markings and histones, signaling
changes between different cell types, and
so on. The author brings us all the way to
this point, keeping Farber and other early
players alive through the narrative.
This book is about giving the full sense
of time and pace and people. The
narrative evokes detail rather than in-
structs. A reader expert in any area will see
what is left out, what is made to sound
simple when the reality is complex. But the
whole story also has a reality, and there
have been so very few authors who can tell
us the whole story of major areas of
medicine or science.
To tell the whole story, the author often
focuses on individuals as heroes. The
device works beautifully. Somehow, with
a cast of Tolstoyian proportions, one can
keep track of the individuals, and continue
to hear their voices even as they come and
go. I could not imagine another way to
accomplish telling such a broad story,
because we remember well-drawn charac-
ters long after we have forgotten about
some particular technical achievement in a
field far from our own. Yet, from the
perspective of understanding the history of
each era in a deeper and more nuanced
way, it is probably good to keep a certain
skepticism in mind.
In the subjects that I know well in
cancer research, I think of the false
tendency to exaggerate the role of a few
individuals in ways that distort both the
actual contributions of individuals and the
actual way in which scientific understand-
ing was achieved. The Nobel Prize winner
Christian de Duve, when asked how he
wanted to be remembered, answered:
I have no such ambition. In the
history of science, my contributions
are minor and would have been
made by someone else had I not
stumbled on them first. They al-
ready appear in textbooks without
mention of my name. I am no
Galileo, Newton, Darwin, Einstein
or Watson and Crick. But I have
had fun and have been rewarded
beyond my deserts. So be it [1].
Nonetheless, a narrative following from
one great person to the next is often a
good way to tell the whole story:
More attention to the History of
Science is needed, as much by
scientists as by historians, and espe-
cially by biologists, and this should
mean a deliberate attempt to under-
stand the thoughts of the great
masters of the past, to see in what
circumstances or intellectual milieu
their ideas were formed, where they
took the wrong turning or stopped
short on the right track. A sense of
the continuity and the progressive and
cumulative character of an advanc-
ing science is the best prophylactic I
can suggest against the manic-de-
pressive alternations of the cult of
vogue and boost, which threatens to
smother the scientific efforts, gigan-
tic as they are, of at least one great
nation [2].
Modern science naturally focuses itself
almost entirely in the present and near
future. But good treatment, research, and
policy require a sense of the historical
continuity and the progressive and cumu-
lative character of advancing science—the
whole story. To learn the whole story of
cancer, read Siddhartha Mukherjee’s mas-
terful book.
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